| Purpose of the guideline: |
Multiple prostate cancer diagnosis and treatment guidelines in Europe and the United States have recommended PSMA PET for early-stage disease, assessment of intermediate- to high-risk prostate cancer, monitoring of biochemical recurrent disease, evaluation of disease progression, and screening and efficacy monitoring of patients undergoing PSMA RLT treatment. In recent years, with the rapid increase in the number of PSMA PET scans in China, there is an urgent need to develop a consensus suitable for the clinical application of prostate cancer molecular imaging in China. This consensus elaborates on the application of PSMA ligand PET in the initial diagnosis, staging, biochemical recurrence diagnosis, and guidance of PSMA RLT treatment of prostate cancer, providing an important basis for precision diagnosis and treatment of prostate cancer based on PSMA PET. |
